HUTCHMED (China) Limited (?HCM) announced that following the contract renewal with the China National Healthcare Security Administration ("NHSA"), the updated National Reimbursement Drug List or "NRDL" effective on January 1, 2025 will continue to include ORPATHYS (savolitinib) at the same terms as the current two-year agreement.
ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor ("TKI"). It received conditional approval in China in June 2021 for the treatment of certain patients with non-small cell lung cancer with MET exon 14 skipping alterations.
ORPATHYS was first included in the NRDL on March 1, 2023. The government in China has placed great importance on improving the affordability of drug treatments for the public.
ORPATHYS is jointly developed by HUTCHMED and AstraZeneca and commercialized by AstraZeneca.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.